Cargando…
Epidermal Growth Factor Receptor Inhibitor Skin Rash Prophylaxis in a Community Oncology Setting
Epidermal growth factor receptor inhibitors (EGFRIs) can potentially cause a debilitating rash despite use of reactive-based treatment. Prophylactic rash management is a controversial rash-mitigating approach. The impact of a prophylactic rash treatment protocol for EGFRIs at a community hospital wa...
Autores principales: | Pepper, Micah S., May, Megan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505548/ https://www.ncbi.nlm.nih.gov/pubmed/31086685 |
Ejemplares similares
-
Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Masago, Katsuhiro, et al.
Publicado: (2018) -
Cutaneous Toxicity in Oncologic Patients Receiving Epidermal Growth Factor Receptor Inhibitors
por: POPA, CRISTINA-MARIA, et al.
Publicado: (2021) -
A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor‐Induced Skin Toxicities
por: Kim, Young Saing, et al.
Publicado: (2019) -
Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti‐Epidermal Growth Factor Receptor‐Induced Acne‐Like Rash: A Randomized Left‐Right Comparative Evaluation (APPEARANCE)
por: Chayahara, Naoko, et al.
Publicado: (2019) -
Community-based study links skin rashes to COVID-19
Publicado: (2021)